It is widely accepted that disorders of the male (uro) genital tract, such as erectile dysfunction
(ED) and benign diseases of the prostate (lower urinary tract symptomatology or benign …

Pharmacological treatment of erectile dysfunction includes all therapeutic modalities based
on the use of erectogenic drugs, regardless of the route of administration. Intracavernous …

Penile erection is mediated by nitric oxide (NO) and its second messenger cyclic guanosine
monophosphate (cGMP). The activity of cGMP is modulated by the enzyme …

An estimated 20 million to 30 million American men have erectile dysfunction (ED). The past
2 decades of research defining erectile physiology and investigating the pathogenesis of ED …

The modern-day management of erectile dys-function reflects a host of advances that have
occurred in the field of sexual medicine, particularly in the past several years. In the …

Erectile dysfunction is a common, multifactorial disorder that is associated with aging and a
range of organic and psychogenic conditions, including hypertension …

Review article Pharmacotherapy for erectile dysfunction Page 1 Review article Pharmacotherapy
for erectile dysfunction Tom F. Lue and Keith L. Lee Keywords： erectile dysfunction· prostaglandin …

The treatment of erectile dysfunction has changed dramatically over the past two decades.
The introduction of the oral agent sildenafil 2 years ago has revolutionized the treatment of …

Introduction Erectile dysfunction (ED) affects between 12.9% and 28.1% of men worldwide,
presenting a strong aged-correlated prevalence. Several pharmacological treatments are …

Nitric oxide (NO) is formed from the conversion of L-arginine by nitric oxide synthase (NOS),
which exists in three isoforms: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS) …